Fujifilm Medical Systems adds IVD solutions

Fujifilm Medical Systems U.S.A. Inc. is adding In Vitro Diagnostics (IVD) to its portfolio of healthcare solutions with the integration of Fujifilm Wako Diagnostics U.S.A. Corporation, a provider of IVD and life science products. The integration will enhance Fujifilm Medical Systems U.S.A. Inc.’s portfolio of diagnostic solutions for its healthcare customers through the addition of IVD clinical lab reagents and biomarkers.

“With an established portfolio of diagnostic imaging solutions to enable treatment planning, diagnosis and healthcare IT, we look forward to expanding our solutions to include IVD,” said Jun Higuchi, president and chief executive officer, Fujifilm Medical Systems U.S.A., Inc. “The addition of IVD to our diagnostic portfolio will enable us to provide clinicians with tools to assess risks of disease development through our biomarkers and our existing diagnostic imaging solutions.”

Fujifilm Wako Diagnostics has an established portfolio of biomarkers to assess the risk for the development of hepatocellular carcinoma (HCC) in patients with chronic liver disease. Its IVD portfolio of solutions also includes IVD reagents and systems focused on areas including disorders of lipid metabolism, lupus, rheumatoid arthritis, coronary heart disease, and diabetes.

The new IVD group will be led by Hidetoshi (Henry) Izawa, vice president of modality solutions and clinical affairs, Fujifilm Medical Systems U.S.A. Inc. As part of his current role, Izawa oversees digital radiography, computed radiography and women’s health groups. Previously, he was responsible for radiology, IVD and endoscopy for Fujifilm France, and was the head of modality for Europe.

“This integration will enable us to leverage our expanded resources at Fujifilm Medical Systems U.S.A. Inc. to offer enhanced clinical support and customer service to IVD customers,” Izawa commented. “We are thrilled to welcome the talented men and women of Fujifilm Wako Diagnostics U.S.A. Corporation to our group to accelerate new innovations in IVD.” – MPO